← All trials
NCT03814187
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2019
- Primary completion
- Aug 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 3700
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The Medicines CompanyLead sponsor
- Mayo ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.